Cosmos Health Inc./$COSM
1D1W1MYTD1Y5YMAX
Capital at risk
About Cosmos Health Inc.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
- Ticker
- $COSM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 163
- Headquarters
- Thessaloniki, Greece
- Website
- www.cosmoshealthinc.com
COSM Metrics
BasicAdvanced
$30M
-
-$0.57
4.17
-
Price and volume
Market cap
$30M
Beta
4.17
52-week high
$1.32
52-week low
$0.16
Average daily volume
2.7M
Financial strength
Current ratio
1.052
Quick ratio
0.674
Long term debt to equity
0.168
Total debt to equity
0.773
Interest coverage (TTM)
-4.91%
Profitability
EBITDA (TTM)
-16.787
Gross margin (TTM)
10.27%
Net profit margin (TTM)
-33.08%
Operating margin (TTM)
-24.65%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-18.42%
Return on equity (TTM)
-104.00%
Valuation
Price to revenue (TTM)
0.174
Price to book
1.16
Price to tangible book (TTM)
1.74
Price to free cash flow (TTM)
-1.29
Free cash flow yield (TTM)
-77.51%
Free cash flow per share (TTM)
-0.23
Growth
Revenue change (TTM)
33.82%
Earnings per share change (TTM)
-35.90%
3-year revenue growth (CAGR)
14.76%
10-year revenue growth (CAGR)
39.58%
3-year earnings per share growth (CAGR)
-54.44%
10-year earnings per share growth (CAGR)
-26.99%
Upcoming events
No upcoming events
COSM News
AllArticlesVideos
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
Accesswire4 days ago
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Accesswire4 days ago
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
Accesswire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.